Lataa...
Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
Chronic myelogenous leukemia (CML) is a common hematological malignancy. Some patients progressing to the blast phase develop chemotherapeutic drug resistance. In the authors' previous study, it was found that the mammalian target of rapamycin (mTOR) pathway was activated in CML and that rapamy...
Tallennettuna:
| Julkaisussa: | Oncol Lett |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6676723/ https://ncbi.nlm.nih.gov/pubmed/31404320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10589 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|